《Cell,2月2日,Maturation and persistence of the anti-SARS-CoV-2 memory B cell response》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2021-02-25
  • Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
    Aurélien Sokal 18
    Pascal Chappert 18
    Giovanna Barba-Spaeth 19
    Jean-Claude Weill 17
    Claude-Agnès Reynaud 17
    Matthieu Mahévas 17, 20
    Show all authors
    Show footnotes
    Published:February 02, 2021DOI:https://doi.org/10.1016/j.cell.2021.01.050

    Summary
    Memory B cells play a fundamental role in host defenses against viruses, but to date, their role has been relatively unsettled in the context of SARS-CoV-2. We report here a longitudinal single-cell and repertoire profiling of the B cell response up to 6 months in mild and severe COVID-19 patients. Distinct SARS-CoV-2 spike-specific activated B cell clones fueled an early antibody-secreting cell burst as well as a durable synchronous germinal center response. While highly mutated memory B cells, including pre-existing cross-reactive seasonal Betacoronavirus-specific clones, were recruited early in the response, neutralizing SARS-CoV-2 RBD-specific clones accumulated with time and largely contributed to the late, remarkably stable, memory B cell pool. Highlighting germinal center maturation, these cells displayed clear accumulation of somatic mutations in their variable region genes over time. Overall, these findings demonstrate that an antigen-driven activation persisted and matured up to 6 months after SARS-CoV-2 infection and may provide long-term protection.

  • 原文来源:https://www.cell.com/cell/fulltext/S0092-8674(21)00093-3
相关报告
  • 《Science,2月10日,Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination》

    • 来源专题:COVID-19科研动态监测
    • 编译者:YUTING
    • 发布时间:2022-02-21
    • Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy. We longitudinally profiled SARS-CoV-2 spike (S)-specific serological and memory B cell (MBC) responses in individuals receiving either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous mRNA booster immunization induced higher serum neutralizing antibody and MBC responses against SARS-CoV-2 variants of concern (VOCs) compared to homologous ChAdOx1 boosting. Specificity mapping of circulating B cells revealed that mRNA-1273 boost immunofocused ChAdOx1-primed responses onto epitopes expressed on prefusion-stabilized S. Monoclonal antibodies isolated from mRNA-1273 boosted participants displayed overall higher binding affinities and increased breadth of reactivity against VOCs relative to those isolated from ChAdOx1-boosted individuals. Overall, the results provide molecular insight into the enhanced quality of the B cell response induced following heterologous mRNA booster vaccination.
  • 《Nature,2月24日,Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-02-26
    • Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses Michael Letko, Andrea Marzi & Vincent Munster Nature Microbiology (2020) Abstract Over the past 20 years, several coronaviruses have crossed the species barrier into humans, causing outbreaks of severe, and often fatal, respiratory illness. Since SARS-CoV was first identified in animal markets, global viromics projects have discovered thousands of coronavirus sequences in diverse animals and geographic regions. Unfortunately, there are few tools available to functionally test these viruses for their ability to infect humans, which has severely hampered efforts to predict the next zoonotic viral outbreak. Here, we developed an approach to rapidly screen lineage B betacoronaviruses, such as SARS-CoV and the recent SARS-CoV-2, for receptor usage and their ability to infect cell types from different species. We show that host protease processing during viral entry is a significant barrier for several lineage B viruses and that bypassing this barrier allows several lineage B viruses to enter human cells through an unknown receptor. We also demonstrate how different lineage B viruses can recombine to gain entry into human cells, and confirm that human ACE2 is the receptor for the recently emerging SARS-CoV-2.